Gain Therapeutics, Inc. - COM (GANX)

CUSIP: 36269B105

Q4 2023 13F Holders as of 31 Dec 2023

Type / Class
Equity / COM
Total 13F shares
1,544,999
Share change
+25,036
Total reported value
$5,044,761
Put/Call ratio
467%
Price per share
$3.26
Number of holders
24
Value change
+$81,758
Number of buys
10
Number of sells
9

Quarterly Holders Quick Answers

What is CUSIP 36269B105?
CUSIP 36269B105 identifies GANX - Gain Therapeutics, Inc. - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of Gain Therapeutics, Inc. - COM (GANX) as of Q4 2023

As of 31 Dec 2023, Gain Therapeutics, Inc. - COM (GANX) was held by 24 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 1,544,999 shares. The largest 10 holders included GREENLIGHT CAPITAL INC, ROYAL BANK OF CANADA, GEODE CAPITAL MANAGEMENT, LLC, CM Management, LLC, VANGUARD GROUP INC, CITADEL ADVISORS LLC, PRELUDE CAPITAL MANAGEMENT, LLC, BRIDGEWAY CAPITAL MANAGEMENT, LLC, NORTHERN TRUST CORP, and RENAISSANCE TECHNOLOGIES LLC. This page lists 24 institutional shareholders reporting positions in this security for the Q4 2023 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.